Figure 3
From: ASBEL, an ANA/BTG3 antisense transcript required for tumorigenicity of ovarian carcinoma
ASBEL downregulates ANA/BTG3 protein, but not mRNA expression.
(a) qRT-PCR analysis of ASBEL and ANA/BTG3 expression in ovarian cancer cell lines transfected with siRNA targeting ASBEL. Prior to fold-change calculation, the values were normalized to the signal generated from GAPDH mRNA. (b) Cell lysates from ovarian cancer cell lines transfected with siRNA targeting ASBEL were subjected to immunoblotting analysis with antibodies against the indicated proteins. α-tubulin was used as a loading control. (c) (Left) qRT-PCR analysis of ANA/BTG3 expression in JHOC5 cells transfected with either the sense or antisense ASBEL expression plasmid. (Right) Cell lysates were subjected to immunoblotting analysis with antibodies against the indicated proteins. α-tubulin was used as a loading control. (d) qRT-PCR analysis of ASBEL and ANA/BTG3 expression in JHOC5 cells infected with a lentivirus expressing an shRNA targeting ANA/BTG3. (e) JHOC5 cells that had been infected with a lentivirus expressing shRNA targeting ANA/BTG3 was transfected with siRNA targeting ASBEL and their viability was assessed. *, P < 0.05.
